JOSEPH JANKOVIC to Movement Disorders
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Movement Disorders.
Connection Strength
23.970
-
Peripherally-induced Movement Disorders: An Update. Tremor Other Hyperkinet Mov (N Y). 2023; 13:8.
Score: 0.681
-
Sports-Related Dystonia. Tremor Other Hyperkinet Mov (N Y). 2021; 11:54.
Score: 0.624
-
Editorial "Parkinsonism across the spectrum of movement disorders and beyond". J Neurol Sci. 2022 Feb 15; 433:120013.
Score: 0.614
-
The Clinical Value of Patient Home Videos in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2021; 11:37.
Score: 0.613
-
Beyond tics: movement disorders in patients with Tourette syndrome. J Neural Transm (Vienna). 2021 08; 128(8):1177-1183.
Score: 0.606
-
Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021 Jan 08; 13(1).
Score: 0.584
-
Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
Score: 0.529
-
The Wide Spectrum of Functional Movement Disorders. JAMA Neurol. 2019 02 01; 76(2):235-236.
Score: 0.511
-
Autoimmune and paraneoplastic movement disorders: An update. J Neurol Sci. 2018 02 15; 385:175-184.
Score: 0.474
-
An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018 Jun 01; 147:84-88.
Score: 0.463
-
Botulinum toxin: State of the art. Mov Disord. 2017 Aug; 32(8):1131-1138.
Score: 0.457
-
Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017 Feb; 13(2):76-78.
Score: 0.443
-
Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
Score: 0.441
-
Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
Score: 0.440
-
Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016 Mar; 12(3):175-85.
Score: 0.416
-
Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016 Apr; 25:1-9.
Score: 0.414
-
Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015 Dec; 30(14):1862-9.
Score: 0.407
-
Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
Score: 0.400
-
The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar; 30(3):313-27.
Score: 0.387
-
Paroxysmal movement disorders. Neurol Clin. 2015 Feb; 33(1):137-52.
Score: 0.387
-
Psychogenic movement disorders. Neurol Clin. 2015 Feb; 33(1):205-24.
Score: 0.387
-
Movement disorders. Neurol Clin. 2015 Feb; 33(1):xv-xvi.
Score: 0.387
-
Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014 Dec; 71(12):1567-72.
Score: 0.383
-
Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):825-32.
Score: 0.382
-
"Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord. 2014 Nov; 29(13):1697-8.
Score: 0.378
-
Parkinson disease subtypes. JAMA Neurol. 2014 Apr; 71(4):499-504.
Score: 0.365
-
Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014 Jan; 11(1):3-5.
Score: 0.359
-
Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013 Aug; 12(8):734-5.
Score: 0.349
-
Movement disorders in cerebrovascular disease. Lancet Neurol. 2013 Jun; 12(6):597-608.
Score: 0.342
-
Yips and other movement disorders in golfers. Mov Disord. 2013 May; 28(5):576-81.
Score: 0.340
-
Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013 May 15; 328(1-2):1-8.
Score: 0.340
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.337
-
Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
Score: 0.335
-
Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012 Aug; 25(4):429-32.
Score: 0.326
-
Movement disorders in autoimmune diseases. Mov Disord. 2012 Jul; 27(8):935-46.
Score: 0.320
-
Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
Score: 0.307
-
Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
Score: 0.292
-
Alcohol in essential tremor and other movement disorders. Mov Disord. 2010 Oct 30; 25(14):2274-84.
Score: 0.288
-
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
Score: 0.283
-
Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009 Sep 08; 73(10):e50-2.
Score: 0.266
-
Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009 Sep; 8(9):844-56.
Score: 0.266
-
Movement disorders. Preface. Neurol Clin. 2009 Aug; 27(3):ix-x.
Score: 0.264
-
Peripherally induced movement disorders. Neurol Clin. 2009 Aug; 27(3):821-32, vii.
Score: 0.264
-
Movement disorders in musicians. Mov Disord. 2008 Oct 30; 23(14):1957-65.
Score: 0.251
-
Psychogenic movement disorders in children. Mov Disord. 2008 Oct 15; 23(13):1875-81.
Score: 0.250
-
Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008 Jan; 7(1):9-11.
Score: 0.237
-
Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
Score: 0.225
-
Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
Score: 0.212
-
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):138-48.
Score: 0.209
-
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
Score: 0.206
-
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
Score: 0.195
-
Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004 Sep-Oct; 27(5):234-44.
Score: 0.188
-
Current opinions and practices in post-stroke movement disorders: Survey of movement disorders society members. J Neurol Sci. 2024 03 15; 458:122925.
Score: 0.181
-
Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004; 18(7):437-52.
Score: 0.180
-
COVID19-associated new-onset movement disorders: a follow-up study. J Neurol. 2023 May; 270(5):2409-2415.
Score: 0.170
-
Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003 Mar; 10(1):68-79.
Score: 0.169
-
Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003 Jan 15; 206(1):59-64.
Score: 0.168
-
Head injury and posttraumatic movement disorders. Neurosurgery. 2002 May; 50(5):927-39; discussion 939-40.
Score: 0.160
-
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001 Dec; 58(12):1970-2.
Score: 0.155
-
Worldwide barriers to genetic testing for movement disorders. Eur J Neurol. 2021 06; 28(6):1901-1909.
Score: 0.149
-
Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001 Jan; 16(1):7-12.
Score: 0.146
-
Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
Score: 0.136
-
Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019 07; 127:32-44.
Score: 0.128
-
Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
Score: 0.120
-
Treatable inherited rare movement disorders. Mov Disord. 2018 01; 33(1):21-35.
Score: 0.116
-
ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
Score: 0.113
-
Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
Score: 0.111
-
Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
Score: 0.111
-
Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
Score: 0.103
-
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
Score: 0.102
-
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
Score: 0.101
-
International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995 Sep; 10(5):533-40.
Score: 0.101
-
Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995 Jun; 18(3):197-214.
Score: 0.099
-
Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015 Feb; 30(2):171-9.
Score: 0.096
-
Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
Score: 0.095
-
Botulinum toxin in movement disorders. Curr Opin Neurol. 1994 Aug; 7(4):358-66.
Score: 0.093
-
Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan; 13(1):100-12.
Score: 0.090
-
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013 Nov; 120(11):1579-89.
Score: 0.085
-
The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr; 28(4):543-7.
Score: 0.084
-
Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
Score: 0.081
-
Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr; 46(1):1-18.
Score: 0.078
-
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
Score: 0.077
-
Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
Score: 0.076
-
Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
Score: 0.075
-
Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011 Aug; 82(8):892-8.
Score: 0.074
-
Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
Score: 0.071
-
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
Score: 0.066
-
Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May; 23(5):466-9.
Score: 0.061
-
Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
Score: 0.060
-
Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988; 49:1-13.
Score: 0.059
-
Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
Score: 0.058
-
The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005 Sep; 76(9):1188-93.
Score: 0.050
-
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul; 75(7):951-7.
Score: 0.046
-
Differential diagnosis and etiology of tics. Adv Neurol. 2001; 85:15-29.
Score: 0.036
-
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
Score: 0.035
-
Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
Score: 0.034
-
Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
Score: 0.034
-
Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
Score: 0.024
-
Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
Score: 0.018
-
Rett syndrome and associated movement disorders. Mov Disord. 1990; 5(3):195-202.
Score: 0.017
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
Score: 0.016
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
Score: 0.014
-
Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
Score: 0.008
-
Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
Score: 0.007
-
Extrapyramidal involvement in Rett's syndrome. Neurology. 1990 Feb; 40(2):293-5.
Score: 0.004